PL397820A1 - Sposób diagnozowania choroby oraz sposób określenia skuteczności leczenia lub oceny prognozy choroby związanej z odpornością lub naczyniowej u osobnika - Google Patents

Sposób diagnozowania choroby oraz sposób określenia skuteczności leczenia lub oceny prognozy choroby związanej z odpornością lub naczyniowej u osobnika

Info

Publication number
PL397820A1
PL397820A1 PL397820A PL39782003A PL397820A1 PL 397820 A1 PL397820 A1 PL 397820A1 PL 397820 A PL397820 A PL 397820A PL 39782003 A PL39782003 A PL 39782003A PL 397820 A1 PL397820 A1 PL 397820A1
Authority
PL
Poland
Prior art keywords
disease
diagnosing
vascular
effectiveness
individual
Prior art date
Application number
PL397820A
Other languages
English (en)
Inventor
Suchitra Sumitran-Holgersson
Original Assignee
Absorber Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Absorber Ab filed Critical Absorber Ab
Publication of PL397820A1 publication Critical patent/PL397820A1/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • G01N2800/245Transplantation related diseases, e.g. graft versus host disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL397820A 2002-05-16 2003-05-16 Sposób diagnozowania choroby oraz sposób określenia skuteczności leczenia lub oceny prognozy choroby związanej z odpornością lub naczyniowej u osobnika PL397820A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38103302P 2002-05-16 2002-05-16

Publications (1)

Publication Number Publication Date
PL397820A1 true PL397820A1 (pl) 2012-07-16

Family

ID=29550055

Family Applications (2)

Application Number Title Priority Date Filing Date
PL373564A PL212661B1 (pl) 2002-05-16 2003-05-16 Sposób izolacji komórki prekursorowej sródblonka
PL397820A PL397820A1 (pl) 2002-05-16 2003-05-16 Sposób diagnozowania choroby oraz sposób określenia skuteczności leczenia lub oceny prognozy choroby związanej z odpornością lub naczyniowej u osobnika

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL373564A PL212661B1 (pl) 2002-05-16 2003-05-16 Sposób izolacji komórki prekursorowej sródblonka

Country Status (17)

Country Link
US (3) US8173372B2 (pl)
EP (1) EP1458853B1 (pl)
AT (1) ATE449838T1 (pl)
AU (1) AU2003241107B2 (pl)
BR (1) BRPI0311182A2 (pl)
CA (1) CA2486119C (pl)
CY (1) CY1109815T1 (pl)
DE (1) DE60330223D1 (pl)
DK (1) DK1458853T3 (pl)
ES (1) ES2337244T3 (pl)
IL (2) IL165250A0 (pl)
NO (1) NO20040174L (pl)
NZ (1) NZ537220A (pl)
PL (2) PL212661B1 (pl)
PT (1) PT1458853E (pl)
SI (1) SI1458853T1 (pl)
WO (1) WO2003098212A2 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
EP1458853B1 (en) * 2002-05-16 2009-11-25 Absorber AB Methods of donor specific crossmatching
EP2041299A4 (en) 2006-07-14 2010-01-13 Aviva Biosciences Corp METHOD AND COMPOSITIONS FOR DETECTION OF RARE CELLS FROM A BIOLOGICAL SAMPLE
EP2051076A1 (en) * 2007-10-18 2009-04-22 Koninklijke Philips Electronics N.V. Interaction of probe molecules and cells as a diagnostic marker
BR112022014417A2 (pt) 2020-01-24 2022-09-13 Pfizer Anticorpos anti-e-selectina, composições e métodos de uso

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
NO155316C (no) 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US4714680B1 (en) * 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5130144B1 (en) * 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4965204A (en) * 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US5026365A (en) * 1987-04-29 1991-06-25 The University Of Massachusetts Method and apparatus for therapeutically treating immunological disorders and disease states
ATE81724T1 (de) * 1987-11-09 1992-11-15 Becton Dickinson Co Verfahren zur analyse haematopoietischer zellen in einer probe.
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5071741A (en) * 1988-04-18 1991-12-10 Cryolife, Inc. Cryoprotective agent and its use in cryopreservation of cellular matter
DE3829766A1 (de) * 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
DE3829752A1 (de) * 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
US5084350A (en) * 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
ES2107537T3 (es) 1991-04-25 1997-12-01 Univ Brown Res Found Vehiculo inmunoaislante biocompatible implantable para suministrar productos terapeuticos seleccionados.
US5257984A (en) * 1991-10-02 1993-11-02 Norfolk Scientific, Inc. Blood collector
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
AU672775B2 (en) 1992-01-21 1996-10-17 Cobe Laboratories Inc. Method of freezing cells and cell-like materials
US5518890A (en) * 1992-11-20 1996-05-21 Mccormick & Company, Inc. Method and apparatus for the quantitation and separation of contaminants from particulate materials
AU7568094A (en) 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5518878A (en) 1993-09-15 1996-05-21 Organogenesis Inc. Cryopreservation of cultured skin or cornea equivalents with agitation
US5482841A (en) * 1994-05-24 1996-01-09 Sangstat Medical Corporation Evaluation of transplant acceptance
US5968753A (en) * 1994-06-14 1999-10-19 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US5840502A (en) * 1994-08-31 1998-11-24 Activated Cell Therapy, Inc. Methods for enriching specific cell-types by density gradient centrifugation
US5580714A (en) 1995-03-08 1996-12-03 Celox Laboratories, Inc. Cryopreservation solution
US5629145A (en) 1995-03-24 1997-05-13 Organ, Inc. Cryopreservation of cell suspensions
KR0176513B1 (ko) * 1995-04-13 1999-04-15 김광호 자기 기록/재생장치
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
US5843633A (en) * 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
WO1998014058A1 (en) 1996-10-03 1998-04-09 The Regents Of The University Of California Cryopreservation of human adult and fetal pancreatic cells and human platelets
US6103536A (en) * 1997-05-02 2000-08-15 Silver Lake Research Corporation Internally referenced competitive assays
EP0893493A3 (de) * 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
US20030100107A1 (en) * 1998-05-29 2003-05-29 Thomas Jefferson University Compositions and methods for generating differentiated human cells
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
US6309643B1 (en) * 1999-04-30 2001-10-30 The Regents Of The University Of California IBD-associated microbial antigens and methods of using same
GB0015923D0 (en) * 2000-06-30 2000-08-23 Astrazeneca Ab Methods
US6984308B2 (en) * 2001-03-06 2006-01-10 Cincinnati Children's Hospital Research Foundation Electrochemical analysis of coenzyme Q10 and reduced coenzyme Q10
EP1423012B1 (en) 2001-08-10 2007-11-14 Imclone Systems, Inc. Medical use of stem cells expressing vegfr-1
WO2003062373A2 (en) * 2001-10-18 2003-07-31 The Children's Hospital Of Philadelphia Methods and materials for the recruitment of endothelial cells
EP1458853B1 (en) * 2002-05-16 2009-11-25 Absorber AB Methods of donor specific crossmatching
ATE423842T1 (de) * 2004-08-13 2009-03-15 Medtronic Inc Isolation der endothelvorläuferzellen-untermengen und verfahren zu ihrer verwendung

Also Published As

Publication number Publication date
WO2003098212B1 (en) 2004-07-29
SI1458853T1 (sl) 2010-04-30
DE60330223D1 (pl) 2010-01-07
PT1458853E (pt) 2010-02-23
IL165250A (en) 2011-03-31
PL373564A1 (pl) 2005-09-05
CY1109815T1 (el) 2014-09-10
NZ537220A (en) 2008-06-30
US20030228638A1 (en) 2003-12-11
AU2003241107B2 (en) 2009-09-03
ES2337244T3 (es) 2010-04-22
EP1458853B1 (en) 2009-11-25
AU2003241107A1 (en) 2003-12-02
US20090142780A1 (en) 2009-06-04
IL165250A0 (en) 2005-12-18
WO2003098212A3 (en) 2004-07-01
US8034635B2 (en) 2011-10-11
BRPI0311182A2 (pt) 2016-06-21
NO20040174L (no) 2004-03-08
PL212661B1 (pl) 2012-11-30
CA2486119A1 (en) 2003-11-27
DK1458853T3 (da) 2010-04-06
EP1458853A2 (en) 2004-09-22
US20050244404A1 (en) 2005-11-03
WO2003098212A2 (en) 2003-11-27
CA2486119C (en) 2011-01-04
ATE449838T1 (de) 2009-12-15
US8173372B2 (en) 2012-05-08

Similar Documents

Publication Publication Date Title
MXPA03003281A (es) Deteccion enzimatica no invasiva de estados asociados con la remodelacion de tejidos.
WO2006085984A3 (en) Immune cell biosensors and methods of using same
WO2006076025A3 (en) Immune cell biosensors and methods of using same
WO2004032621A3 (en) Techniques for identifying molecular structures and treating cell types lining a body lumen using fluorescence
EP2293074A3 (en) Method for diagnosing neuro-degenerative disease
MXPA02006145A (es) Metodo para el aislamiento de arn de especimenes de tejido incluido en parafina fijo en formalina.
IL142647A0 (en) A method and kit for measuring proteasome activity
WO2003081201A3 (en) Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same
WO2001043764A3 (en) Methods for treating pervasive development disorders
WO2004055519A3 (en) Specific markers for pancreatic cancer
WO2005078624A3 (en) A method of recruiting patients for a clinical study
WO2004043223A3 (en) Compositions and methods for the diagnosis and treatment of sepsis
CY1109815T1 (el) Μεθοδοι διασταυρουμενης συμβατοτητας ειδικες δοτη
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
ATE428928T1 (de) Verfahren zur einführung von heterologischen zellen in fische
WO2004045517A3 (en) Method for the diagnosis and treatment of vascular disease
AU2003228984A8 (en) Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
WO2001092877A3 (en) Method of identifying and/or isolating stem cells
WO2005098444A3 (en) Monocarboxylate transporters expressed in cancer cells
ATE392619T1 (de) Verfahren zur diagnose von synovialen oder osteoartikulären erkrankungen
WO2001004343A3 (en) A method for determining the prognosis of cancer patients by measuring levels of bag expression
EP1601682A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
AU2003260815A8 (en) Method for the rapid assessment of the presence and viability of bacterial cells and use thereof________________________
EP1141703A4 (en) METHODS FOR DETERMINING INCREASED RISK FOR A WOMAN CARRYING A FETUS WITH DOWN SYNDROME
WO2006022682A3 (en) Method and compositions for treating diseases targeting cd49b

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)